{
    "nctId": "NCT05134519",
    "briefTitle": "RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer",
    "officialTitle": "Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Coupling Agent (RC48-ADC) for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression (Seraph)",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Pathological complete response rate (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Enrolled were \u2265 18 years of age and \\< 80 years of age\n2. Female or male breast cancer\n3. Patients with early or locally advanced breast cancer who are HER2-positive, have a tumor larger than 2 cm and/or have lymph node metastasis: HER2-positive is defined as 3 + by immunohistochemistry, or 2 + by immunohistochemistry, with a positive FISH test.\n4. Left ventricular score \u2265 55%\n5. ECOGPS score 0 or 1\n6. Able to understand the test requirements, willing and able to comply with the test and follow-up procedures\n7. Adequate organ function\n\nExclusion Criteria:\n\n1. cardiac, hepatic, renal, or psychiatric disease history\n2. History of other malignancy within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}